Fraker DL - Search Results

1

Metaiodobenzylguanidine and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma.

Canter RJ, Zhou R, Kesmodel SB, Zhang Y, Heitjan DF, Glickson JD, Leeper DB, Fraker DL. Canter RJ, et al. Among authors: fraker dl. Ann Surg Oncol. 2004 Mar;11(3):265-73. doi: 10.1245/aso.2004.05.019. Ann Surg Oncol. 2004. PMID: 14993021

2

Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.

Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Thom AK, et al. Among authors: fraker dl. J Clin Oncol. 1995 Jan;13(1):264-73. doi: 10.1200/JCO.1995.13.1.264. J Clin Oncol. 1995. PMID: 7799030 Clinical Trial.

3

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.

Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Fraker DL, et al. J Clin Oncol. 1996 Feb;14(2):479-89. doi: 10.1200/JCO.1996.14.2.479. J Clin Oncol. 1996. PMID: 8636761 Clinical Trial.

4

Isolated limb perfusion for malignant melanoma.

Alexander HR Jr, Fraker DL, Bartlett DL. Alexander HR Jr, et al. Among authors: fraker dl. Semin Surg Oncol. 1996 Nov-Dec;12(6):416-28. doi: 10.1002/(SICI)1098-2388(199611/12)12:6<416::AID-SSU7>3.0.CO;2-D. Semin Surg Oncol. 1996. PMID: 8914206 Review.

5

Surgical issues in the management of melanoma.

Fraker DL. Fraker DL. Curr Opin Oncol. 1997 Mar;9(2):183-8. doi: 10.1097/00001622-199703000-00014. Curr Opin Oncol. 1997. PMID: 9161799 Review.

6

Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.

Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Fraker DL, et al. Cancer J Sci Am. 1995 Jul-Aug;1(2):122-30. Cancer J Sci Am. 1995. PMID: 9166465

7

Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.

Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL. Bartlett DL, et al. Among authors: fraker dl. Cancer. 1997 Dec 1;80(11):2084-90. doi: 10.1002/(sici)1097-0142(19971201)80:11<2084::aid-cncr7>3.0.co;2-x. Cancer. 1997. PMID: 9392330

8

Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.

Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Alexander HR Jr, et al. Among authors: fraker dl. J Clin Oncol. 1998 Apr;16(4):1479-89. doi: 10.1200/JCO.1998.16.4.1479. J Clin Oncol. 1998. PMID: 9552055 Clinical Trial.

9

Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma.

Feldman AL, Alexander HR Jr, Bartlett DL, Fraker DL, Libutti SK. Feldman AL, et al. Among authors: fraker dl. Ann Surg Oncol. 1999 Sep;6(6):562-7. doi: 10.1007/s10434-999-0562-x. Ann Surg Oncol. 1999. PMID: 10493624

10

Hyperthermic regional perfusion for melanoma and sarcoma of the limbs.

Fraker DL. Fraker DL. Curr Probl Surg. 1999 Nov;36(11):841-907. doi: 10.1016/s0011-3840(99)80008-2. Curr Probl Surg. 1999. PMID: 10569114 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

349 results

Search Page

Filters